

The logo for Gynecologic Cancer Intergroup is located in the top left corner. It consists of a rectangular box with a black border. Inside the box, the text "GYNECOLOGIC" is written in white capital letters on a black background. Below it, "CANCER INTERGROUP" is written in white capital letters on a black background. At the bottom of the box, there is a smaller line of text: "An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers". The background of the box is decorated with horizontal stripes of various colors: green, yellow, blue, purple, and orange.

**GYNECOLOGIC
CANCER INTERGROUP**

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers

Meta-analysis group meeting Report to GA

Munich 2018

Xavier Paoletti & Ros Glasspool

ONGOING TRIALS

Trial Name	Trial Description	# pts enrolled/total	Lead Group/Contact person
SEPOC	<p>Surrogate Endpoints in Ovarian Cancer</p> <p>Pilot project for the MA group</p> <p>Primary objective: to assess surrogate endpoints for OS of</p> <ul style="list-style-type: none"> • Progression free survival defined as per GCIG criteria and by RECIST alone • Overall response using RECIST v1.1 <p>Study CA-125 evolution as a surrogate endpoint of PFS</p> <p>Secondary projects</p> <p>Validation of GCIG CA125 criteria</p> <p>Kelim validation/CA125 dynamics</p> <p>Prognostic / predictive factors</p> <p>Histology</p> <p>Elderly</p>	<p>>11000 patients 17 trials</p> <p>EORTC DoCaCel CCTG MRC HECOG SGCTG MITO JGOG NSGO MANGO CCTG MITO GINECO SGCTG JGOG ERASMUS GOG</p>	<p>GINECO/SGCTG Xavier Paoletti/Ros Glasspool</p>

ONGOING TRIALS

Trial Name	Trial Description	# pts enrolled/total	Lead Group/Contact person
<p>PFS benefit with PARPi maintenance therapy in ovarian cancer</p>	<p>Aim To investigate subgroups, defined by clinical and pathologic characteristics, that could predict greater PFS benefit with PARP maintenance therapy in both germline, somatic BRCA and non-BRCA ovarian cancer patient populations</p> <p>Subgroups: Age Time to progression with penultimate platinum: Response to last platinum: Number of previous platinum regimens Prior bevacizumab therapy: BRCA: BRCA 1 vs BRCA2 vs somatic BRCA</p>	<p>Awaiting data</p>	<p>ANZGOG/Chee Lee</p>

CRF Standardization for Future Trials

With A. Reuss (chair of the stat committee) and the Harmonization committee

- Proposal to standardize the description of baseline characteristics in our future trials for first line ovarian
 - Minimum set of variables to collect
 - Minimum set of categories that should be collected
 - Thesaurus for variable names and coding
- Plan: consensus approach in 3 rounds:
 - Round 1
 - Circulate a list of candidate variables to each GCIG group
 - Collect suggestions / comments
 - Update the list of candidates
 - Round 2
 - Circulate the updated list for comments
 - uPdate the list
 - Round 3
 - Submit the list to the harmonization committee for validation

First line Adjuvant Treatment in Endometrial Cancer ?

First step

- Updated systematic review
 - What are the key questions
 - What can be addressed from existing data
 - New trial proposals